rawfin.tv
Natera Partners With Diakonos for Melanoma Trial Using Signatera
MarketsstocksAI Generated

Natera Partners With Diakonos for Melanoma Trial Using Signatera

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Natera Inc. (NTRA) has announced a partnership with Diakonos Research to integrate its Signatera MRD testing into a refractory melanoma immunotherapy trial. The collaboration aims to track circulating tumor DNA (ctDNA) to monitor treatment efficacy.

NTRABiotechClinical TrialsMelanomaPartnershipsHealthcare

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks